Your browser doesn't support javascript.
loading
Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).
Ruggenenti, Piero; Cortinovis, Monica; Trillini, Matias; Parvanova, Aneliya; Abbate, Manuela; Satriano, Chiara; Salvetti, Ferdinando; Bossi, Antonio C; Trevisan, Roberto; Perna, Annalisa; Peracchi, Tobia; Rubis, Nadia; Diadei, Olimpia; Martinetti, Davide; Gaspari, Flavio; Fontana, Luigi; Remuzzi, Giuseppe.
Afiliação
  • Ruggenenti P; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Cortinovis M; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Trillini M; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Parvanova A; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Abbate M; Research Group on Global Health and Human Development, University of the Balearic Islands (UIB) and Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain.
  • Satriano C; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Salvetti F; Unit of Ophthalmology, Casa di cura Beato Palazzolo, Bergamo, Italy.
  • Bossi AC; Unit of Diabetology and Metabolic Diseases, Azienda Socio-Sanitaria Territoriale Bergamo Ovest, Treviglio-Caravaggio-Romano, Bergamo, Italy.
  • Trevisan R; Unit of Endocrinology 1 and Diabetology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Perna A; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Peracchi T; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Rubis N; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Diadei O; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Martinetti D; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Gaspari F; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy.
  • Fontana L; Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, and Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Department of Clinical and Experimental Sciences, Brescia University Medical School, Brescia, Italy.
  • Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Bergamo, Italy. Electronic address: giuseppe.remuzzi@marionegri.it.
Diabetes Res Clin Pract ; 185: 109804, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35219762
ABSTRACT

AIMS:

In type 2 diabetic patients with obesity, hyperfiltration is a risk factor for accelerated glomerular filtration rate (GFR) decline and is ameliorated by calorie restriction (CR). We assessed whether CR-induced amelioration of hyperfiltration could translate into slower long-term GFR decline in this population.

METHODS:

In this academic, single-center, parallel-group, prospective, randomized, open-label, blinded endpoint trial, consenting >40-year-old patients with type 2 diabetes, BMI ≥27 kg/m2, creatinine <1.2 mg/dL and albuminuria ≤300 mg/24 h were randomized (11) to two-year 25% CR (n = 53) or standard diet (SD, n = 50). Primary outcome was 6-month measured GFR. Analyses were by modified intention-to-treat.

RESULTS:

At 6 months GFR decreased by 5.16 ± 10.03 mL/min (P = 0.001) with CR, and by 0.98 ± 9.71 mL/min (P = 0.497) with SD. Between-group difference was significant (P = 0.044). GFR decline from 6 to 24 months was significant with SD (P < 0.01), but not with CR (P = 0.075). Between-group difference, however, was not significant (P = 0.414). Body weight, BMI, waist circumference, systolic blood pressure, HbA1c, blood glucose, serum triglycerides decreased and ApoA-I concentration increased with CR. No changes were observed with SD. Between-group differences were significant. CR was tolerated well.

CONCLUSIONS:

In obese type 2 diabetic patients, CR ameliorated glomerular hyperfiltration and several cardiovascular risk factors, and blunted long-term GFR decline. TRIAL REGISTRATION NCT01930136.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Diabetes Res Clin Pract Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Diabetes Res Clin Pract Ano de publicação: 2022 Tipo de documento: Article